ATLANTA, Nov. 21 /PRNewswire-FirstCall/ -- AtheroGenics, Inc. , a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that Russell M. Medford, M.D., Ph.D., President and Chief Executive Officer of AtheroGenics, will present a company overview and update at the Lazard Capital Markets Annual Life Sciences Conference in New York City on Tuesday, November 29, 2005 at 11:00 a.m. Eastern time. The presentation will be available via a live audio webcast. A link to the webcast can be found in the investor section of the Company’s website, under the Investor Calendar tab, at http://www.atherogenics.com/investor/stock.html. A seven-day replay of the webcast will be available beginning approximately one hour following the live presentation using that same link.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040730/ATATHEROGENICSLOGO )
About AtheroGenics
AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including heart disease (atherosclerosis), rheumatoid arthritis and asthma. The Company has two drug development programs currently in the clinic. AtheroGenics’ lead compound, AGI-1067, is being evaluated in the pivotal Phase III clinical trial called ARISE, as an oral therapy for the treatment of atherosclerosis. AGI-1096 is a novel, oral agent in Phase I that is being developed for the prevention of organ transplant rejection in collaboration with Astellas. AtheroGenics also has preclinical programs in rheumatoid arthritis and asthma utilizing its novel vascular protectant(R) technology. For more information about AtheroGenics, please visit www.atherogenics.com.
Photo: http://www.newscom.com/cgi-bin/prnh/20040730/ATATHEROGENICSLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comAtheroGenics, Inc.
CONTACT: Donna L. Glasky, Corporate Communications of AtheroGenics, Inc.,+1-678-336-2517, or investor@atherogenics.com; or Investors, Lilian Sternof Stern Investor Relations, Inc., +1-212-362-1200, or lilian@sternir.com;or Media, Katie Brazel of Fleishman Hillard, +1-404-739- 0150, orbrazelk@fleishman.com
